Possible Correlation between Some Biologic Effects and the Clinical Course in Patiens Treated with Continuous Infusion of Interleukin-2 plus Alpha-2 Interferon for Metastatic Renal Cell Carcinoma
Restricted accessResearch articleFirst published online October, 1994
Possible Correlation between Some Biologic Effects and the Clinical Course in Patiens Treated with Continuous Infusion of Interleukin-2 plus Alpha-2 Interferon for Metastatic Renal Cell Carcinoma
Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response.
Methods
Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte.
Results
Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33%) and 3 stable disease (20%): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a “score” system, was also related to a better clinical response.
Conclusions
Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.
AebersoldP., HyattC., JohnsonS., HinesK., KorkarL., SandersM., LotzeM., TapallanS., YangJ., RosembergS.A.: Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.J. Natl. Cancer Inst., 83: 932–937, 1991.
2.
AtkinsM.B., MierJ.W., ParkinsonD.R., GouldJ.A., BerkmanE.M., KaplanM.M.: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.N. Engl. J. Med., 318: 1557–1563, 1988.
3.
AtzpodienJ., KirchnerH.: Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasm.Klin. Wochenschr., 68: 1–11. 1990.
4.
AtzpodienJ., KirchnerH., FranksC.R., KorferA., PalmerP.A., EversP., PoliwodaH.: Outpatient treatment of advanced human cancer using a combination of recombinant interleukin-2 and interferon alpha 2b.Insights Immunother., 1: 47–49, 1990.
5.
BalkwillF.R., SmythJ.F.: Interferons in cancer therapy: a reappraisal.Lancet, 2: 317–319, 1987.
6.
BarthsH.H., AdlerM., RingertR.H.: Sequential therapy of recombinant interferon alpha and recombinant interleukin-2 in patients with advanced renal cell cancer.Proc. Am. Soc. Clin. Oncol., 9: 556, 1990.
7.
BelldegrunA., MuulL.M., RosembergS.A.: Interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: isolation, characterization and antitumor activity.Cancer Res., 48: 206–214, 1988.
8.
BesanaC., SabbadiniM.G., CortiC., Di LuccaG., FoppoliM., MarcattiM., HeltaiS., RugarliC.: Autoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: correlation with tumor regression.Tumori, 77: 339–341, 1991.
9.
BoccoliG., MasciulliR., RuggeriE.M., CarliniP., GiannellaG., MontesoroE., MastroberardinoG., IsacchiG., TestaU., CalabresiF., PeschleC.: Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high dose interleukin-2 bolus treatment.Cancer Res., 50: 5795–5800, 1990.
10.
BrandaM.J., TarnowskiD., DavatelisV.: Interaction of recombinant interferons with recombinant interleukin-2: differential effects of natural killer cell activity and IL-2 activated killer cells.Int. J. Cancer., 37: 787–793, 1986.
11.
CameronR.B., McIntoshJ.K., RosembergS.A.: Synergistic antitumor effects of combination immunotherapy with recombinant hybrid alpha interferon in the treatment of established murine hepatic metastases.Cancer Res., 48: 5810–5817, 1988.
12.
EnokiharaH., FurusawaS., NakakuboH., KajitaniH., NagashimaS., SaitoK., ShishidoH., HitoshiY., TakatsuK., NomaT., ShimizuA., HonjoT.: T cells from eosinophilic patients produce IL-2 stimulation.Blood, 73: 1809–1813, 1989.
13.
FerraarJ.J., BenjaminW.R., HilfikerJ.L.: The biochemistry, biology and role of interleukin-2 in the induction of T cell and antibody forming B-cell responses.Immunol. Rev., 63: 129–166, 1982.
14.
FeruglioC., ZambelloR., TrentinL., BulianP., FranceschiT., CettoG.L., SemenzaioG.: Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy: Effects of activation with recombinant interleukin-2.Cancer, 69: 2525–2531, 1992.
15.
FortisC., FerreroE., BiffiM., HeltaiS., BesanaC., BucciE., TresoldiM., RugarliC.: Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.Cancer Immunol. Immunother., 33: 128–132, 1991.
16.
GrimmE.A., MazumderA., ZangH.Z., RosembergS.A.: The lymphokine activated killer cell phenomenon: lysis of NK resistent fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes.J. Exp. Med., 155: 1823–1841, 1982.
17.
HancockB.W., ReesR.C.: Interleukin-2 and cancer therapy.Cancer Cells.2: 29–32, 1990.
18.
HirshM., LiptonA., HarveyH.: Phase I study of interleukin-2 and interferon alpha 2a as outpatient therapy for patients with advanced malignancy.J. Clin. Oncol., 8: 1657–1663, 1990.
19.
KimB., WarnakaP.: Enhanced survival of interferon alpha augmented interleukin-2 therapy of pulmonary metastases: efficacy comparable to interleukin-2 and lymphokine activated killer cells.J. Surg. Res., 50: 40–46, 1991.
20.
KradinR.L., KurnickJ.T., LazarusD.S., PrefferF.I., DubinettS.M., PintoC.E., GriffordJ., DavidsonE., GroveB., CallahanR.J., StraussH.W.: Tumor infiltrating lymphocytes and IL-2 in treatment of advanced cancer.Lancet, 1: 577–580, 1989.
21.
KroemerG., WickG.: The role of interleukin-2 in autoimmunity.Immunol. Today, 10: 246–251, 1989.
22.
MattijsenE.J.M., De MulderP.H.M., Van LiessunP.A., CarstensF.H.M., WagenerB.J.T.: Hypothyroidism and goitre during interleukin-2 therapy without LAK cells.Lancet, 1: 224, 1989.
23.
McIntoshJ.K., MuleJ.J., KrosnickJ.A., RosembergS.A.: Combination cytokine immunotherapy with tumor necrosis factor. Interleukin-2 and alpha interferon and its synergistic antitumor effects in mice.Cancer Res., 49: 1408–1414, 1989.
24.
MitchellM.S.: Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and IL-2. Semin.Oncol., 19: 80–87, 1992.
25.
MorantR., RichnerJ., EversP., SennH.J.: Interleukin-2 and interferon alpha combination immunotherapy in patients with metastatic renal cell carcinoma.Proc. Am. Soc. Clin. Oncol., 5: 549, 1990.
26.
MorganD.A., RuscettiF.W., GalloR.C.: Selective in vitro growth of T lymphocytes from normal human bone marrow.Science, 193: 1007–1008, 1976.
27.
PaciucciP.A., MandeliJ., OlecksowiczL., AmeglioF., HollandJ.F.: Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion.Am. J. Med., 89: 308–312, 1990.
28.
PalmerP.A., VinkeJ., PhilipT., NegrierS., AtzpodienJ., KirchnerH., OskamR., FrankC.R.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann.Oncol., 3: 475–480, 1992.
29.
PerezR., PadavicK., KrigelR., WeinerL.: Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon.Cancer, 67: 2512–2517, 1991.
30.
PerkinsH.A.: The Human Major Histocompatibility Complex (MHC). In: Basic and Clinical Immunology.FundenbergH.H., StitesD.P., CaldwellJ.L., WellsJ.V. (Eds.). Lange, Los Altos, pp. 165–174, 1978.
RobertsK., LotzeM.T., RosembergS.A.: Separation and functional studies of the human lymphokine-activated killer cells.Cancer Res., 47: 4366–4371, 1987.
33.
RosembergS.A., GrimmE.A., McGrogan: Biological activity of recombinant interleukin-2 produced in E. Coli.Science, 223: 1412–1415, 1984.
34.
RosembergS.A.: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: Important Advances in Oncology.De VitaV.T.Jr., HellmanS., RosembergS.A. (Eds.). J.B. Lippincott, Philadelphia, pp. 55–91, 1986.
35.
RosembergS.A., LotzeM.T., MuulL.M., ChangA.E., AvisF.P., LeitmanW.M., RobertsonC.N., LeeR.E., RudinJ.T., SeippC.A., SimpsonC.G., WhiteD.E.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.N. Engl. J. Med., 316: 889–897, 1987.
36.
RosembergS.A., LotzeM.T., MuleJ.J.: New approaches to the immunotherapy of cancer using interleukin-2. Ann.Intern. Med., 108: 853–864, 1988.
37.
RosembergS.A., LongoD.L., LotzeM.T.: Principles and applications of biologic therapy. In: Cancer Principles and Practice of Oncology. III Ed.De VitaV.T.Jr., HellmanS., RosembergS.A. (Eds.). J.B. Lippincott, Philadelphia, pp. 301–347, 1989.
38.
RosembergS.A., LotzeM.T., YangJ.C., LinehanW., SeippC., CalabroS., KarpS.E., SherryR.M., SteinberG.S., WhiteD.E.: Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer.J. Clin. Oncol., 7: 1863–1874, 1989.
39.
ScalzoS., GengaroA., BoccoliG., MasciulliR., GiannellaG., SalvoG., MarollaP., CarliniP., MassiminiG., HoldenerE.E., TestaU., CalabresiF., PeschleC.: Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma.Eur. J. Cancer., 26: 1152–1156, 1990.
40.
SchoofD.D., GramoliniB.A., DavidsonD.L.: Adoptive immunotherapy of human cancer using low-dose IL-2 and lymphokine-activated killer cells.Cancer Res., 48: 5007–5010, 1988.
41.
SchwartzentruberD.J.: In vitro predictors of clinical response in patients receiving IL-2 based immunotherapy.Curr. Opinion Oncol., 5: 1055–1058, 1993.
